Radiolabeling, stability studies, and pharmacokinetic evaluation of thulium-170-labeled acyclic and cyclic polyaminopolyphosphonic acids

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 10, 2013, Pages 737-745

  Vats, Kusum ^a   Das, Tapas ^a   Sarma, Haladhar D ^a   Banerjee, Sharmila ^a   Pillai, M R A ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

bone pain palliation; radiolabeled phosphonic acid; Thulium 170

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID TM 170; 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8,11 TETRAMETHYLENE PHOSPHONIC ACID TM 170; DIETHYLENETRIAMINEPENTAMETHYLENE PHOSPHONIC ACID TM 170; PHOSPHONIC ACID DERIVATIVE; THULIUM; THULIUM 170; TRIETHYLENETETRAMINEHEXAMETHYLENE PHOSPHONIC ACID TM 170; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; COMPLEX FORMATION; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; RAT;

ANIMALS; BONE AND BONES; ISOTOPE LABELING; PALLIATIVE CARE; PHOSPHOROUS ACIDS; POLYAMINES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; THULIUM; TISSUE DISTRIBUTION;

EID: 84887871275     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1475     Document Type: Article

References (41)

1. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of Sm-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987;28:495.
2. Maini CL, Bergomi S, Romano L, et al. 153Sm-EDTMP for bone pain palliation in metastases. Eur J Nucl Med Mol Imaging 2004;31(Suppl. 1):S171.
3. Das T, Pillai MRA. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol 2013;40:23.
4. Twycross RG, Fairfield S. Pain in far-advanced cancer. Pain 1982;14:303.
5. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982;50:1913.
6. Paes FM, Ernani V, Hosein P, et al. Radiopharmaceuticals: When and how to use them to treat metastatic bone pain. J Support Oncol 2011;9:197.
7. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010;40:89.
8. Fischer M, Kampen WU. Radionuclide therapy of bone metastases. Breast Care 2012;7:100.
9. Lewington VJ. Bone seeking radionuclides for therapy. J Nucl Med 2005;46:38S.
10. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone metastasis from osseous metastasis. J Nucl Med 2004;45:1358.
11. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269.
12. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biological and physical background. Semin Nucl Med 1992;22:11.
13. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of breast with wide spread metastases to bone. Am J Roentgenol 1950;64:559.
14. Silberstein EB. The treatment of painful osseous metastases with phosphorus-32 labeled phosphonates. Semin Oncol 1993; 20:10.
15. Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 1987;14:219.
16. Mertens WC, Still L, Porter AT. Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship. Am J Clin Oncol 1993;16:238.
17. Ketring AR. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol 1987;14:223.
18. Atkins HL. Overview of nuclides for bone pain palliation. Appl Radiat Isot 1998;49:277.
19. McEwan AJB. Use of radionuclides for palliation of bone metastases. Semin Radiat Oncol 2000;10:103.
20. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of Samarium-153-EDTMP in metastatic cancer. J Nucl Med 1989;30:1814.
21. Das T, Chakraborty S, Sarma HD, et al. 170Tm-EDTMP: A potential cost effective alternative to 89SrCl2 for bone pain palliation. Nucl Med Biol 2009;36:561.
22. Chakraborty S, Das T, Banerjee S, et al. 177Lu-EDTMP: A viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm 2008;23:202.
23. Ando A, Ando I, Tonami N, et al. 177Lu-EDTMP: A potential therapeutic bone agent. Nucl Med Commun 1998;19:587.
24. Chakraborty S, Das T, Unni PR, et al. 177Lu labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun 2002;23:67.
25. Das T, Chakraborty S, Unni PR, et al. 177Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot 2002;57:177.
26. Das T, Chakraborty S, Sarma HD, et al. 177Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta 2008;96:55.
27. Ando A, Ando I, Tonami N, et al. Production of 105Rh-EDTMP and its bone accumulation. Appl Radiat Isot 2000; 52:211.
28. Banerjee S, Samuel G, Kothari K, et al. Tc-99m and Re-188 complexes of tetraphosphonate ligands and their biodistribution pattern in animal models. Nucl Med Biol 2001; 28:205.
29. Mathew B, Chakraborty S, Das T, et al. 175Yb labeled polyaminopolyphosphonates as potential agents for bone pain palliation. Appl Radiat Isot 2004;60:635.
30. Laznicek M, Lazincova A, Budsky F, et al. Comparison of biological characteristics of EDTMP complexes with 99mTc, 111In and 153Sm in rats. Appl Radiat Isot 1994;45:949.
31. Chakraborty S, Das T, Banerjee S, et al. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation. Nucl Med Commun 2004;25:1169.
32. O'Mara RE, Subramanian G. Experimental agents for skeletal imaging. Semin Nucl Med 1972;2:38.
33. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001;12:7.
34. Garlich JR, McMillan K, Masterson TT, et al. Chemistry of novel macrocyclic aminophosphonic acid chelates of rare earth radionuclides and their in vivo biodistribution. J Nucl Med 1993;34:244.
35. Moedritzer K, Irani RR. The direct synthesis of a-amino methyl phosphonic acids: Mannich-type reaction with orthophosphorus acid. J Org Chem 1966;31:1603.
36. Sarma HD, Das T, Banerjee S, et al. Biologic evaluation of a novel of 188Re-labeled porphyrin in mice tumor model. Curr Radiopharm 2010;25:47.
37. Farhangi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451.
38. Senthamizhchelvan S, Hobbs RF, Song H, et al. Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high risk osteosarcoma. J Nucl Med 2012;53:215.
39. Porter AT. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone. Eur Urol 1994;26:20.
40. Bos SD. An overview of current clinical experience with strontium-89 (Metastron-). Prostate 1994;25:23.
41. Spahn I, Coenen HH, Qaim SM. Enhanced production possibility of the therapeutic radionuclides 64Cu, 67Cu and 89Sr via (n,p) reactions induced by fast spectral neutrons. Radiochim Acta 2004;92:183.